rare kidney disease

San Diego, California | April 13, 2026 Travere Therapeutics, Inc. has announced that the U.S. Food and Drug Administration...

BASEL, Oct. 16, 2025 — Novartis announced positive final Phase III results from its APPLAUSE-IgAN trial, confirming that Fabhalta®...

MONMOUTH, N.J., Sept. 18, 2025 A new investigational therapy, JD-004, has received Orphan Drug Designation (ODD) from the U.S. Food...